Spotlight on Oncology

Credits: 0.75 CME
Optimizing the Use of Screening and Imaging in Women With Dense Breasts
Deepa Sheth, MD
Vindico

Optimizing the Use of Screening and Imaging in Women With Dense Breasts

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 26, 2019
Expires: November 25, 2020
45 minutes to complete

This activity has been updated to include additional resources. Please check the educational tools section of this activity to access the additional resources.

Accredited By

This continuing medical education activity is provided by

Endorsed by

Target Audience

The intended audience for the activity is radiologists, obstetrician-gynecologists, primary care physicians and other health care professionals involved in imaging, or referral for imaging, of patients with dense breasts.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the effects that dense breasts have on cancer risk, as well as their effect on the interpretation of imaging results used in diagnosis and screening.
  • Summarize evidence-based classification criteria used to measure breast density.
  • Determine when it is appropriate to use advanced imaging in patients with dense breasts.
  • Assess the safety of gadolinium-based contrast agents for use in advanced magnetic resonance imaging.
  • Evaluate processes and procedures that can improve the ordering of conventional and advanced imaging for women with dense breasts.
  • Incorporate processes that improve the multidisciplinary management of patients with dense breasts that are undergoing screening or diagnostic follow-up.

Activity Description

Screening mammography has remained the most useful tool for breast cancer detection and has consistently demonstrated a reduction in breast cancer mortality. Dense breast tissue absorbs significantly more radiation during mammography than fatty breast tissue, reducing the accuracy of mammography in women with this condition. However, other imaging modalities exist to increase the accuracy of detecting cancer in dense breast tissue. In this continuing medical education panel discussion, expert physicians from multiple fields will explore alternative imaging modalities for examining breast tissue, in addition to mammography, to diagnose breast cancer in women.

Faculty

Activity Chair:
Deepa Sheth, MD
Assistant Professor of Radiology
Breast Imaging Center
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Faculty:
Susan Hong, MD, MPH
Director of Cancer Survivorship
Associate Professor of Medicine and Surgery
University of Illinois
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Iris Romero, MD, MS
Associate Professor
Department of Ob/Gyn
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Guerbet LLC.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 26, 2019
Expires: November 25, 2020
45 minutes to complete

This activity has been updated to include additional resources. Please check the educational tools section of this activity to access the additional resources.

Accredited By

This continuing medical education activity is provided by

Endorsed by

Target Audience

The intended audience for the activity is radiologists, obstetrician-gynecologists, primary care physicians and other health care professionals involved in imaging, or referral for imaging, of patients with dense breasts.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the effects that dense breasts have on cancer risk, as well as their effect on the interpretation of imaging results used in diagnosis and screening.
  • Summarize evidence-based classification criteria used to measure breast density.
  • Determine when it is appropriate to use advanced imaging in patients with dense breasts.
  • Assess the safety of gadolinium-based contrast agents for use in advanced magnetic resonance imaging.
  • Evaluate processes and procedures that can improve the ordering of conventional and advanced imaging for women with dense breasts.
  • Incorporate processes that improve the multidisciplinary management of patients with dense breasts that are undergoing screening or diagnostic follow-up.

Activity Description

Screening mammography has remained the most useful tool for breast cancer detection and has consistently demonstrated a reduction in breast cancer mortality. Dense breast tissue absorbs significantly more radiation during mammography than fatty breast tissue, reducing the accuracy of mammography in women with this condition. However, other imaging modalities exist to increase the accuracy of detecting cancer in dense breast tissue. In this continuing medical education panel discussion, expert physicians from multiple fields will explore alternative imaging modalities for examining breast tissue, in addition to mammography, to diagnose breast cancer in women.

Faculty

Activity Chair:
Deepa Sheth, MD
Assistant Professor of Radiology
Breast Imaging Center
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Faculty:
Susan Hong, MD, MPH
Director of Cancer Survivorship
Associate Professor of Medicine and Surgery
University of Illinois
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Iris Romero, MD, MS
Associate Professor
Department of Ob/Gyn
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Guerbet LLC.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Oncology Presentations

0.75 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Small Cell Lung Cancer: Optimism Through Immunotherapeutic Approaches

Small Cell Lung Cancer: Optimism Through Immunotherapeutic Approaches

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
/ MOC point(s)
Released: May 15, 2020
Expires: May 14, 2021
45 minutes to complete

Accredited By

Target Audience

This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.

Learning Objectives

  • Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
  • Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
  • Incorporate immunotherapy into the management of patients with SCLC where appropriate
  • Identify and manage immune-related adverse events associated with checkpoint inhibitors

Activity Description

In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.

Statement of Educational Need

Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.

Agenda

This activity will address the following topics:

  • Role of the immune system in tumor pathogenesis
  • Rationale for immunotherapy in SCLC
  • Brief overview of the mechanism of action of immunotherapy
  • Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
  • Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
  • Description of ongoing and planned clinical trials of immunotherapy for SCLC
  • Identifying patients who may benefit from immunotherapy

Faculty

Hossein Borghaei, DO, MS (Chair)
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA

Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.

Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.

Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).

Taofeek K. Owonikoko, MD, PhD, MSCR
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
Co-Leader
, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA

Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.

Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.

Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).

Kristen Kreamer, CRNP, AOCNP, APRN, BC
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.

Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.

Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).

Cedric White (Patient)
Cedric White has nothing to disclose.

Conflict of Interest Policy/Disclosure Statement

AKH planners and reviewers have no financial relationships to disclose.
RMEI Medical Education, LLC planners and managers have no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points 0 patient safety in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps:

Step 1: Review and successfully complete the activity

Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth

Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
/ MOC point(s)
Released: May 15, 2020
Expires: May 14, 2021
45 minutes to complete

Accredited By

Target Audience

This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.

Learning Objectives

  • Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
  • Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
  • Incorporate immunotherapy into the management of patients with SCLC where appropriate
  • Identify and manage immune-related adverse events associated with checkpoint inhibitors

Activity Description

In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.

Statement of Educational Need

Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.

Agenda

This activity will address the following topics:

  • Role of the immune system in tumor pathogenesis
  • Rationale for immunotherapy in SCLC
  • Brief overview of the mechanism of action of immunotherapy
  • Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
  • Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
  • Description of ongoing and planned clinical trials of immunotherapy for SCLC
  • Identifying patients who may benefit from immunotherapy

Faculty

Hossein Borghaei, DO, MS (Chair)
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA

Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.

Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.

Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).

Taofeek K. Owonikoko, MD, PhD, MSCR
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
Co-Leader
, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA

Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.

Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.

Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).

Kristen Kreamer, CRNP, AOCNP, APRN, BC
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.

Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.

Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).

Cedric White (Patient)
Cedric White has nothing to disclose.

Conflict of Interest Policy/Disclosure Statement

AKH planners and reviewers have no financial relationships to disclose.
RMEI Medical Education, LLC planners and managers have no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points 0 patient safety in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps:

Step 1: Review and successfully complete the activity

Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth

Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

1.00 CME / CNE / CPE
Rush University Medical Center
Navigating the Prostate Cancer Disease Continuum - Evolving Strategies in the Management of HSPC and CRPC

Navigating the Prostate Cancer Disease Continuum - Evolving Strategies in the Management of HSPC and CRPC

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  • Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
  • Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  • Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
  • Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Advances in High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Advances in High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the recently modified recommendations for the risk stratification and classification of patients with AML and how this classification impacts treatment decisions
  • Incorporate recently approved therapies into clinical treatment of patients with high-risk or relapsed/refractory AML
  • Discuss the novel investigational agents under development and review the considerations for their potential clinical use in patients with AML

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for acute myeloid leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with acute myeloid leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Mark Levis, MD, PhD
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Conflict of Interest Policy/Disclosure Statement

Dr. Levis receives research funding from Astellas Global Pharma, FujiFilm, and Novartis. Dr. Levis provides consulting/honoraria to Agios, Daiichi-Sankyo, Amgen, Menarini, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Agios, and Astellas.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the recently modified recommendations for the risk stratification and classification of patients with AML and how this classification impacts treatment decisions
  • Incorporate recently approved therapies into clinical treatment of patients with high-risk or relapsed/refractory AML
  • Discuss the novel investigational agents under development and review the considerations for their potential clinical use in patients with AML

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for acute myeloid leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with acute myeloid leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Mark Levis, MD, PhD
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Conflict of Interest Policy/Disclosure Statement

Dr. Levis receives research funding from Astellas Global Pharma, FujiFilm, and Novartis. Dr. Levis provides consulting/honoraria to Agios, Daiichi-Sankyo, Amgen, Menarini, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Agios, and Astellas.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Emerging Strategies for the Management of Chronic Lymphocytic Leukemia

Emerging Strategies for the Management of Chronic Lymphocytic Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers
  • Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines
  • Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL
  • Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of chronic lymphocytic leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for chronic lymphocytic leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with chronic lymphocytic leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joao Ascensao, MD
Washington DC Veterans Affairs Medical Center
Washington, DC


Conflict of Interest Policy/Disclosure Statement

Dr. Ascensao has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers
  • Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines
  • Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL
  • Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of chronic lymphocytic leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for chronic lymphocytic leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with chronic lymphocytic leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joao Ascensao, MD
Washington DC Veterans Affairs Medical Center
Washington, DC


Conflict of Interest Policy/Disclosure Statement

Dr. Ascensao has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Advancing Strategies in Prostate Cancer: Individualizing Treatment Plans Based on the Rapidly Evolving Landscape and Disease Continuum

Advancing Strategies in Prostate Cancer: Individualizing Treatment Plans Based on the Rapidly Evolving Landscape and Disease Continuum

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by


Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Recommend individualized, evidence-based treatment plans for advanced prostate cancer patients in the VHA, DoD and MHS settings, incorporating and appropriately sequencing new agents and combinations while considering standards-of-care guidelines, expert recommendations, disease and patient characteristics, as well as patients’ needs/preferences
  • Assess recent clinical trial data on efficacy and safety of currently available therapies, investigational therapies, and novel combination therapies for advanced prostate cancer
  • Describe current and planned clinical trials for prostate cancer patients assessing a variety of agents including hormone, cytotoxic, immuno-oncology, bone-directed, molecularly targeted & other novel therapies across the disease continuum

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancers. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Julie Graff, MD
Associate Professor Medicine
Oregon Health & Science University
Portland, OR


Conflict of Interest Policy/Disclosure Statement

Julie Graff, MD
Research Grants: Janssen, Astellas, Sanofi, Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by


Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Recommend individualized, evidence-based treatment plans for advanced prostate cancer patients in the VHA, DoD and MHS settings, incorporating and appropriately sequencing new agents and combinations while considering standards-of-care guidelines, expert recommendations, disease and patient characteristics, as well as patients’ needs/preferences
  • Assess recent clinical trial data on efficacy and safety of currently available therapies, investigational therapies, and novel combination therapies for advanced prostate cancer
  • Describe current and planned clinical trials for prostate cancer patients assessing a variety of agents including hormone, cytotoxic, immuno-oncology, bone-directed, molecularly targeted & other novel therapies across the disease continuum

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancers. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Julie Graff, MD
Associate Professor Medicine
Oregon Health & Science University
Portland, OR


Conflict of Interest Policy/Disclosure Statement

Julie Graff, MD
Research Grants: Janssen, Astellas, Sanofi, Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes

Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by


Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
  • Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
  • Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joshua Richter, MD

Mount Sinai Hospital
New York, NY


Conflict of Interest Policy/Disclosure Statement

Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau, for Janssen and Celgene.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc. and Celgene.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by


Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
  • Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
  • Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joshua Richter, MD

Mount Sinai Hospital
New York, NY


Conflict of Interest Policy/Disclosure Statement

Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau, for Janssen and Celgene.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc. and Celgene.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Guidance on the Latest Developments, Treatment Strategies, and Emerging Clinical Data in the Management of Multiple Myeloma

Expert Guidance on the Latest Developments, Treatment Strategies, and Emerging Clinical Data in the Management of Multiple Myeloma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience 

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Apply evidence-based best clinical practices for treating multiple myeloma patients throughout the disease continuum
  • Summarize the latest data from finalized and ongoing clinical trials, including the evaluation of new classes of therapeutics and review the contexts for their potential clinical use in patients with multiple myeloma
  • Determine the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Carol Ann Huff, MD
Carol Ann Huff, MD
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD


Conflict of Interest Policy/Disclosure Statement

Dr. Huff has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Consultant: Johnson and Johnson, Sanofi, Karyopharm.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s). Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Amgen, Celgene, and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience 

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Apply evidence-based best clinical practices for treating multiple myeloma patients throughout the disease continuum
  • Summarize the latest data from finalized and ongoing clinical trials, including the evaluation of new classes of therapeutics and review the contexts for their potential clinical use in patients with multiple myeloma
  • Determine the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Carol Ann Huff, MD
Carol Ann Huff, MD
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD


Conflict of Interest Policy/Disclosure Statement

Dr. Huff has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Consultant: Johnson and Johnson, Sanofi, Karyopharm.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s). Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Amgen, Celgene, and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

0.75 CME / CNE
Forefront Collaborative
HER Disease, Shared Perspectives: A multi-disciplinary discussion on HR+, HER2- metastatic breast cancer treatment options

HER Disease, Shared Perspectives: A multi-disciplinary discussion on HR+, HER2- metastatic breast cancer treatment options

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
45 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals including radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may also benefit from participation in the educational activity. 

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate and apply emerging clinical data and evolving strategies for the treatment of metastatic breast cancer to optimize the outcomes of individual patients.
  • Analyze patient and disease characteristics that influence treatment selection for patients with HR+, HER2- metastatic breast cancer.

Activity Description

The treatment landscape for HR+, HER2- metastatic breast cancer has gone through a paradigm shift in treatment, with the advent of targeted therapies. From emerging clinical data to treatment selection, a multidisciplinary panel led by Hope Rugo, MD, FASCO, team up with Vandana Abramson, MD, Erika Hamilton, MD, and Lauren Czapla, NP, to provide a practical update for practicing clinicians on key treatment advances, and analyzing patient and disease characteristics influencing treatment selection for patients with HR+, HER2- metastatic breast cancer.

Statement of Educational Need

With the recent approvals, and new clinical data, medical oncologists, nurse practitioners, and physician assistants are faced with three challenges:
  • Staying abreast of the rapidly expanding evidence base to inform treatment of HR+, HER2- metastatic breast cancer (knowledge-based gaps).
  • Interpreting emerging data of approved and investigational therapies to best guide clinical decision making (competency-based gaps).
  • Analyzing patient and disease characteristics that inform treatment selection for a patient with HR+, HER2- metastatic breast cancer.

Agenda

  • Overview of HR+, HER2- emerging targeted therapies.
  • Tumor–board-style discussion of a patient with HR+, HER2- metastatic breast cancer.
  • Visual guide for treatment selection (algorithm) for HR +, HER2- metastatic breast cancer.

Faculty

Hope S. Rugo, MD, FASCO
Professor of Medicine,
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California


Vandana G. Abramson, MD, MTR
Associate Professor of Medicine,
Division of Hematology-Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Hope S. Rugo, MD, FASCO
    Contracted research—Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi-Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics (all funding to UC Regents)
    Travel support to academic meetings—Daiichi-Sankyo, Mylan, Pfizer, Amgen, Merck, AstraZeneca, MacroGenics, and Puma

    Erika P. Hamilton, MD
    Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
    Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
    Advisory board—Lilly (institutional compensation only, not personal)
    Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

    Vandana G. Abramson, MD, MTR
    Advisory board—Novartis
    Contracted research—Novartis and Genentech

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103993. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.75 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME/CNE evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
45 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals including radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may also benefit from participation in the educational activity. 

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate and apply emerging clinical data and evolving strategies for the treatment of metastatic breast cancer to optimize the outcomes of individual patients.
  • Analyze patient and disease characteristics that influence treatment selection for patients with HR+, HER2- metastatic breast cancer.

Activity Description

The treatment landscape for HR+, HER2- metastatic breast cancer has gone through a paradigm shift in treatment, with the advent of targeted therapies. From emerging clinical data to treatment selection, a multidisciplinary panel led by Hope Rugo, MD, FASCO, team up with Vandana Abramson, MD, Erika Hamilton, MD, and Lauren Czapla, NP, to provide a practical update for practicing clinicians on key treatment advances, and analyzing patient and disease characteristics influencing treatment selection for patients with HR+, HER2- metastatic breast cancer.

Statement of Educational Need

With the recent approvals, and new clinical data, medical oncologists, nurse practitioners, and physician assistants are faced with three challenges:
  • Staying abreast of the rapidly expanding evidence base to inform treatment of HR+, HER2- metastatic breast cancer (knowledge-based gaps).
  • Interpreting emerging data of approved and investigational therapies to best guide clinical decision making (competency-based gaps).
  • Analyzing patient and disease characteristics that inform treatment selection for a patient with HR+, HER2- metastatic breast cancer.

Agenda

  • Overview of HR+, HER2- emerging targeted therapies.
  • Tumor–board-style discussion of a patient with HR+, HER2- metastatic breast cancer.
  • Visual guide for treatment selection (algorithm) for HR +, HER2- metastatic breast cancer.

Faculty

Hope S. Rugo, MD, FASCO
Professor of Medicine,
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California


Vandana G. Abramson, MD, MTR
Associate Professor of Medicine,
Division of Hematology-Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Hope S. Rugo, MD, FASCO
    Contracted research—Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi-Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics (all funding to UC Regents)
    Travel support to academic meetings—Daiichi-Sankyo, Mylan, Pfizer, Amgen, Merck, AstraZeneca, MacroGenics, and Puma

    Erika P. Hamilton, MD
    Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
    Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
    Advisory board—Lilly (institutional compensation only, not personal)
    Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

    Vandana G. Abramson, MD, MTR
    Advisory board—Novartis
    Contracted research—Novartis and Genentech

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103993. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.75 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME/CNE evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

0.50 CME / CNE
Forefront Collaborative
HER Disease, Shared Decisions: Engaging the patient when choosing HR+, HER2- metastatic breast cancer treatment options

HER Disease, Shared Decisions: Engaging the patient when choosing HR+, HER2- metastatic breast cancer treatment options

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
30 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals such as radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may benefit from participation in the proposed educational activities. 

Learning Objectives

  • Upon completion of this activity, participants should be able to:
    • Engage patients with HR+ HER2- mBC in a shared decision making (SDM) process on the goals of treatment, treatment plan development, and treatment modification.
    • Identify strategies to enhance symptom management and increase adherence to treatment.

Activity Description

The advent of CDK4/6 inhibitors as effective treatment for mBC is a great milestone for patients with mBC but requires a deep understanding of the benefits and risks of the treatment options. From SDM simulation to symptom management, breast cancer specialists, Erika Hamilton, MD, and Lauren Czapla, NP, team up to provide a practical update for integrating SDM in practice and strategies to enhance symptom management and increase adherence.

Statement of Educational Need

Cancer treatment decision making is challenging because there are multiple effective therapies that are interconnected, with a complex interplay between their benefits and risks. SDM is a best practice health care process used to help patients but is not fully integrated in breast cancer care.

Agenda

  • Overview of SDM to improve treatment adherence and patient outcomes.
  • Simulation of SDM with a patient with HR+, HER2- mBC.
  • Overview of strategies to enhance symptom management and increase adherence to treatment.

Faculty

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Erika P. Hamilton, MD
    • Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
      Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
      Advisory board—Lilly (institutional compensation only, not personal)
      Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103994. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
30 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals such as radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may benefit from participation in the proposed educational activities. 

Learning Objectives

  • Upon completion of this activity, participants should be able to:
    • Engage patients with HR+ HER2- mBC in a shared decision making (SDM) process on the goals of treatment, treatment plan development, and treatment modification.
    • Identify strategies to enhance symptom management and increase adherence to treatment.

Activity Description

The advent of CDK4/6 inhibitors as effective treatment for mBC is a great milestone for patients with mBC but requires a deep understanding of the benefits and risks of the treatment options. From SDM simulation to symptom management, breast cancer specialists, Erika Hamilton, MD, and Lauren Czapla, NP, team up to provide a practical update for integrating SDM in practice and strategies to enhance symptom management and increase adherence.

Statement of Educational Need

Cancer treatment decision making is challenging because there are multiple effective therapies that are interconnected, with a complex interplay between their benefits and risks. SDM is a best practice health care process used to help patients but is not fully integrated in breast cancer care.

Agenda

  • Overview of SDM to improve treatment adherence and patient outcomes.
  • Simulation of SDM with a patient with HR+, HER2- mBC.
  • Overview of strategies to enhance symptom management and increase adherence to treatment.

Faculty

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Erika P. Hamilton, MD
    • Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
      Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
      Advisory board—Lilly (institutional compensation only, not personal)
      Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103994. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

1.00 CME / CNE / CPE
Rush University Medical Center
Evolving Strategies for Using CDK 4/6 Inhibitors in the Treatment of HR+ (HER2-) Advanced Breast Cancer

Evolving Strategies for Using CDK 4/6 Inhibitors in the Treatment of HR+ (HER2-) Advanced Breast Cancer

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate recent clinical trial data for CDK4/6 inhibitors currently approved for first-line treatment of advanced breast cancer
  2. Select appropriate first-line therapy for patients with HR+ (Her2-) advanced breast cancer on the basis of patient and disease characteristics
  3. Develop strategies for the management of adverse events associated with CDK4/6 inhibitor therapy

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of breast cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for breast cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with breast cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago
Chicago, IL


Conflict of Interest Policy/Disclosure Statement

Rita Nanda, MD, Disclosures:
Research Grant from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, Odonate Therapeutics, Pfizer, Seattle Genetics.
Consultant to Aduro, AstraZeneca, Athenex, Celgene, Daiichi Sankyo Inc., Genentech, MacroGenics, Merck, Novartis, Pfizer, Puma, Syndax.
G1Theraputics (DSMB); OBI Pharma (Clinical Steering Committee)

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate recent clinical trial data for CDK4/6 inhibitors currently approved for first-line treatment of advanced breast cancer
  2. Select appropriate first-line therapy for patients with HR+ (Her2-) advanced breast cancer on the basis of patient and disease characteristics
  3. Develop strategies for the management of adverse events associated with CDK4/6 inhibitor therapy

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of breast cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for breast cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with breast cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago
Chicago, IL


Conflict of Interest Policy/Disclosure Statement

Rita Nanda, MD, Disclosures:
Research Grant from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, Odonate Therapeutics, Pfizer, Seattle Genetics.
Consultant to Aduro, AstraZeneca, Athenex, Celgene, Daiichi Sankyo Inc., Genentech, MacroGenics, Merck, Novartis, Pfizer, Puma, Syndax.
G1Theraputics (DSMB); OBI Pharma (Clinical Steering Committee)

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Pages